Form 4: Director Clay Siegall Boosts Stake in Shattuck Labs

Shattuck Labs Director Clay B. Siegall acquired 128,054 shares of common stock and an equal number of warrants in a private placement.

Summary

• Clay B. Siegall, a Director of Shattuck Labs, Inc. (STTK), acquired 128,054 shares of common stock and accompanying warrants.
• The acquisition occurred on August 25, 2025, as part of a private placement under a securities purchase agreement dated August 4, 2025.
• The combined price for each share and accompanying warrant was $0.8677.
• The warrants allow for the purchase of up to 128,054 additional shares of common stock at an exercise price of $1.0846 per share.
• The warrants become exercisable on or after their issuance date until 30 days following the public announcement of data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s).

Sentiment

Score: 7

Explanation: The acquisition by a Director signals confidence in the company's future. While a private placement can be dilutive, insider buying is generally viewed as a positive indicator. The contingent nature of the warrants ties future upside to clinical success, which is a standard but speculative element in biotech.

Positives

• A Director increasing their stake in the company through a private placement can signal confidence in the company's future prospects and strategy.
• The private placement provides capital to the Issuer, Shattuck Labs, Inc.

Negatives

• The private placement could result in dilution for existing shareholders, although the specific impact is not detailed in this filing.

Risks

• The exercisability of the warrants is contingent upon the public announcement of specific clinical trial data for SL-325 (Phase 1 receptor occupancy and safety data, and Phase 2 trial design), introducing a risk tied to the success and timing of these clinical milestones.
• Future clinical trial results for SL-325 may not be positive, which could impact the value of the warrants and the company's stock.

Future Outlook

The future value and exercisability of the acquired warrants are directly tied to the public announcement of Phase 1 clinical trial data for SL-325, including receptor occupancy and safety, and the design of planned Phase 2 clinical trials. This indicates a forward-looking focus on key clinical development milestones for Shattuck Labs.

Management Comments

• The transaction reflects a direct action by a company Director to increase their beneficial ownership in Shattuck Labs, Inc.

Industry Context

Private placements are a common method for biotechnology companies like Shattuck Labs to raise capital, especially when funding clinical trials and drug development. Insider participation in such placements can be viewed positively, signaling management's belief in the company's pipeline. The contingent nature of the warrants on clinical trial data is typical for early-stage biotech investments, where future value is heavily dependent on research and development success.

Comparison to Industry Standards

• Private placements with insider participation are a standard financing mechanism in the biotech sector, often used to fund specific development programs.
• The structure of warrants tied to clinical milestones is a common incentive and risk-sharing mechanism in biotech investments, similar to those seen in early-stage funding rounds for companies developing novel therapies like those from Moderna (MRNA) or BioNTech (BNTX) in their earlier stages, where success is highly dependent on trial outcomes.

Related Party Transactions

• The Reporting Person, Clay B. Siegall, is a Director of Shattuck Labs, Inc., and participated as an accredited investor in the private placement, making this a related party transaction.

Stakeholder Impact

• Shareholders: Potential confidence boost due to insider buying, but also potential dilution from the private placement.
• Investors: Provides insight into management's conviction and the company's financing activities, influencing investment decisions.
• Company: Receives capital from the private placement to fund operations and clinical development.

Next Steps

• Public announcement of data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data.
• Public announcement of the design of the planned Phase 2 clinical trial(s) for SL-325.

Key Dates

Recommendation

Director Clay B. Siegall's acquisition of shares and warrants in a private placement indicates confidence in Shattuck Labs. However, the warrants' exercisability is contingent on the public announcement of Phase 1 clinical trial data for SL-325 and the design of Phase 2 trials, introducing a speculative element tied to clinical success. This transaction provides a positive signal but does not fundamentally alter the company's risk profile or immediate financial performance, warranting a 'hold' until further clinical data is released.

Keywords

Shattuck Labs, STTK, Clay B. Siegall, Director, Insider Trading, Form 4, Private Placement, Warrants, Common Stock, Biotechnology, Clinical Trial, SL-325, Equity Acquisition